Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian cancer cells

Cancer Epidemiol. 2013 Aug;37(4):512-7. doi: 10.1016/j.canep.2013.02.008. Epub 2013 Mar 29.

Abstract

Background: Despite advances in treatment, ovarian cancer is the most lethal gynecologic malignancy. Therefore significant efforts are being made to develop novel strategies for the treatment of ovarian cancer. Salinomycin has been shown to be highly effective in the elimination of cancer stem cells both in vitro and in vivo. The present study focused on investigating important cell signaling molecules such as Akt and NF-κB during salinomycin-induced apoptosis in cisplatin resistant ovarian cancer cells (A2780cis).

Methods: MTT assay was performed to determine cell viability. Flow cytometry and DNA fragmentation assay were performed to analyze the effect on cell cycle and apoptosis. The expression of apoptosis related proteins was evaluated by Western blot analysis.

Results: The cell viability was significantly reduced by salinomycin treatment in a dose dependent manner. The flow cytometry result showed an increase in sub-G1 phase. Salinomycin inhibited the nuclear transportation of NF-κB, and downregulated Akt expression. Declined Bcl-2, activation of caspase-3 and increased PARP cleavage triggered apoptosis. Moreover, DNA fragmentation assay also revealed apoptotic induction.

Conclusion: The result suggested that salinomycin-induced apoptosis in A2780cis was associated with inhibition of Akt/NF-κB. It may become a potential chemotherapeutic agent for the cisplatin resistant ovarian cancer therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Blotting, Western
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cisplatin / pharmacology
  • DNA Fragmentation / drug effects
  • Dose-Response Relationship, Drug
  • Down-Regulation / drug effects
  • Drug Resistance, Neoplasm
  • Female
  • Flow Cytometry
  • Humans
  • NF-kappa B / antagonists & inhibitors
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / pathology
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Pyrans / administration & dosage
  • Pyrans / pharmacology*

Substances

  • Antineoplastic Agents
  • NF-kappa B
  • Pyrans
  • salinomycin
  • Proto-Oncogene Proteins c-akt
  • Cisplatin